[
  {
    "ts": null,
    "headline": "Immutep Limited (IMMP): Firm Reports Positive Data from Trials",
    "summary": "Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The firm revealed that a Phase 2 study of efti in combination with radiotherapy and Merck’s Keytruda showed significant […]",
    "url": "https://finnhub.io/api/news?id=802a2662f33467ffe3e811e3f40b8b1951236cc1339775f327149523c899f64b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765393996,
      "headline": "Immutep Limited (IMMP): Firm Reports Positive Data from Trials",
      "id": 137750081,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The firm revealed that a Phase 2 study of efti in combination with radiotherapy and Merck’s Keytruda showed significant […]",
      "url": "https://finnhub.io/api/news?id=802a2662f33467ffe3e811e3f40b8b1951236cc1339775f327149523c899f64b"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in. Guggenheim lifted the price target on Merck & Co., Inc. (NYSE:MRK) to $122 from $104 on December 5 while maintaining a Buy rating on the shares. The firm cited the inclusion of probability-adjusted revenues for Winrevair in the population investigated in […]",
    "url": "https://finnhub.io/api/news?id=b089883dea464bcac2b4b3de14f4e282affb077b428882ed2af47f7be4471ecc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765384121,
      "headline": "Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104",
      "id": 137750082,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in. Guggenheim lifted the price target on Merck & Co., Inc. (NYSE:MRK) to $122 from $104 on December 5 while maintaining a Buy rating on the shares. The firm cited the inclusion of probability-adjusted revenues for Winrevair in the population investigated in […]",
      "url": "https://finnhub.io/api/news?id=b089883dea464bcac2b4b3de14f4e282affb077b428882ed2af47f7be4471ecc"
    }
  },
  {
    "ts": null,
    "headline": "2 Pharmaceutical Stocks to Buy at a Discount",
    "summary": "Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.",
    "url": "https://finnhub.io/api/news?id=eafcb5a84e891732caa98815c12cd8c615616d3e47f1a39edcc06d6c5195e1aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765380000,
      "headline": "2 Pharmaceutical Stocks to Buy at a Discount",
      "id": 137750083,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.",
      "url": "https://finnhub.io/api/news?id=eafcb5a84e891732caa98815c12cd8c615616d3e47f1a39edcc06d6c5195e1aa"
    }
  },
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) Could Be A Buy For Its Upcoming Dividend",
    "summary": "It looks like Merck & Co., Inc. ( NYSE:MRK ) is about to go ex-dividend in the next four days. The ex-dividend date is...",
    "url": "https://finnhub.io/api/news?id=a50856e3a607c36517d8eae372125908f9b81112fd9883f4cb4dba19c8aa8d9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765362444,
      "headline": "Merck (NYSE:MRK) Could Be A Buy For Its Upcoming Dividend",
      "id": 137750084,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "It looks like Merck & Co., Inc. ( NYSE:MRK ) is about to go ex-dividend in the next four days. The ex-dividend date is...",
      "url": "https://finnhub.io/api/news?id=a50856e3a607c36517d8eae372125908f9b81112fd9883f4cb4dba19c8aa8d9f"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
    "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
    "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765362409,
      "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
      "id": 137747724,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307043297/image_1307043297.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
      "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29"
    }
  },
  {
    "ts": null,
    "headline": "Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk",
    "summary": "Explore undervalued Novo Nordisk (NVO) vs. Eli Lilly, key growth insights, and investment risks.",
    "url": "https://finnhub.io/api/news?id=614c134a33e647cb51682ced84828d369bf8c32664de7c0902784ed0e04eab7b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765359546,
      "headline": "Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk",
      "id": 137747549,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182825316/image_182825316.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Explore undervalued Novo Nordisk (NVO) vs. Eli Lilly, key growth insights, and investment risks.",
      "url": "https://finnhub.io/api/news?id=614c134a33e647cb51682ced84828d369bf8c32664de7c0902784ed0e04eab7b"
    }
  }
]